
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc. is strategically positioned to benefit from an anticipated improvement in valuation as it navigates the mixed performance influenced by market dynamics and impending reimbursement changes in the advanced wound care segment. The company's ability to generate solid operating profits is expected to enhance its market share, particularly as reimbursement rates are set to rise slightly in 2026. Additionally, with a comprehensive product portfolio and significant growth opportunities in underpenetrated markets, Organogenesis Holdings is poised for a favorable trajectory in the regenerative medicine sector.
Bears say
Organogenesis Holdings Inc faces a negative outlook primarily due to significant risks related to lower-than-expected growth of its PuraPly product line, potential adverse impacts from Medicare Part B pricing on amniotic products, and challenges posed by competitive pressures that may hinder market share gains. Additionally, the company might encounter difficulties from Medicare Administrative Contractors and a slower uptake of new products, compounded by negative clinical data outcomes that could undermine market confidence. Financially, the company's investment in the ReNu program has accrued substantial costs of approximately $30 million for FY24, pushing back potential clearance timelines and reflecting the ongoing burden of increasing research and development expenditures without a corresponding improvement in revenue prospects.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares